2019-09-13
2019-09-13
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-14
2019-09-14
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-15
2019-09-15
Plenary Hall
Ballroom A
Ballroom B
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
07:00 - 19:00
Registration
07:30 - 08:30
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
Jacques Galipeau, MD
University of Wisconsin - Madison, USA
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
William Faubion, MD
Mayo Clinic, USA
07:30 - 08:30
Q&O Track 1: Media Fills
Q&O Track 1: Media Fills image
Rosemarie Bell,B.App.Sc Micro/Biochem MASM (Chair)
QIMR Berghofer Medical Research Institute/Q-Gen Cell Therapeutics, Australia
Q&O Track 1: Media Fills image
Adrian Gee, PhD
Baylor College of Medicine, USA
Aisha Khan, MS, MBA
University of Miami, USA
08:45 - 10:15
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Gil Van Bokkelen, PhD
Athersys, USA
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Etienne Sokal, MD, PhD
Promethera, Belgium
10:15 - 10:45
Coffee Break
10:45 - 12:15
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Daniel Weiss, MD, PhD (Chair)
University of Vermont, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Tracy Webb, DVM, PhD (Chair)
Colorado State University, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Andrew Hoffman, DVM, DVSc, DACVIM
University of Pennsylvania School of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Kyla Ortved, DVM, PhD
University of Pennsylvania School of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Aimee Colbath, VMD, PhD, DACVS-LA
Michigan State University College of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Dori Borjesson, BA, DVM, MPVM, PhD
UC Davis School of Veterinary Medicine, USA
10:45 - 12:15
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene image
Lynn O’Donnell, PhD (Chair)
Ohio State University, James Cancer Hospital Columbus, USA
Eric Gilles
Mayo Clinic IMPACT, USA
Kathryn Melsop
Stanford Laboratory for Cell & Gene Medicine, USA
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene image
Rosemarie Bell, B.App.Sc Micro/Biochem MASM,
QIMR Berghofer Medical Research Institute/ Q-Gen Cell Therapeutics, Australia
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene image
Jacques Galipeau, MD
University of Wisconsin - Madison, USA
10:45 - 12:15
Oral Abstracts Session 1
Oral Abstracts Session 1 image
Patrick Hanley, PhD (Chair)
Children’s National Health System, USA
12:15 - 13:45
Lunch
12:30 - 13:30
Fill/ Finish Challenges and Opportunities for Automation (Corporate Tutorial Hosted by Fresenius-Kabi)
13:45 - 15:15
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Robert Deans, PhD (Chair)
BlueRock Therapeutics, USA
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Dan Kaufman, MD, PhD
University of California San Diego, USA
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Stephanie Protze, PhD
University of Toronto, Canada
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Robert Deans, PhD
15:15 - 15:30
Coffee Break
15:30 - 17:00
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Mitchell Cairo, MD (Chair)
New York Medical College, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Mitchell Cairo, MD
New York Medical College, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Jeffrey Medin, PhD
Medical College of Wisconsin, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Paul Orchard, MD
University of Minnesota, USA
15:30 - 17:00
Q&O Track 3: Stability
Karl Stasko, MPH (Chair)
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Karl Stasko, MPH
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Q&O Track 3: Stability image
Jackie Damen, PhD
Senior Scientific Advisor, Hematopoiesis, Canada
Q&O Track 3: Stability image
Rosemarie Bell, B.App.Sc Micro/Biochem MASM,
QIMR Berghofer Medical Research Institute/ Q-Gen Cell Therapeutics, Australia
15:30 - 17:00
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Laertis Ikonomou, PhD (Chair)
Boston University, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Peter Marks, MD, PhD
Center for Biologics Evaluation and Research, FDA, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Lynne Boxer, DVM
Center for Veterinary Medicine, FDA, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Ajay Kuriyan, MD, MS
Department of Ophthalmology, University of Rochester Medical Center, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Kristin Matthews, PhD
Rice University's Baker Institute for Public Policy, USA
17:00 - 18:00
Breaking Bottlenecks – The Training, Development, and Staffing Challenge (Corporate Symposium Hosted By ISCT ESP Committee & CellCAN)
Emily Hopewell, PhD
ISCT ESP Committee Member, ISCT Global Treasurer, Indiana University School of Medicine, USA
Craig Hasilo, Msc, PhD(C)
CellCAN, Canada
18:00 - 18:30
Welcome Address
18:30 - 20:30
Welcome & Networking Reception Sponsored by FUJIFILM Cellular Dynamics
07:00 - 17:00
Registration
07:30 - 08:30
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Lizette Caballero, BS, MLS(ASCP)CM (Chair)
UCSF Blood and Marrow Transplant Lab, USA
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Paul Eldridge, PhD
UNC Lineberger Comprehensive Cancer Center, USA
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Olive Sturtevant, MHP, MT(ASCP)SBB
Dana-Farber CMCF, USA
07:30 - 08:30
Morning Session 3 – Meet the Experts: CAR T and other Cell “Vehicles”
Morning Session 3 –   Meet the Experts: CAR T and other Cell “Vehicles” image
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
07:30 - 08:30
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Kurt Gunter, MD (Chair)
Cell Medica Inc., USA
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Peiman Hematti, MD
University of Wisconsin-Madison School of Medicine and Public Health, USA
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Cynthia Molina
Triumvira, USA
08:45 - 10:15
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Denis-Claude Roy, MD, FRCPC
Hopital Maisonneuve-Rosemont, Canada
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Lisa Butterfield, PhD
University of Pittsburgh Department of Medicine, USA
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Sumithira Vasu, MBBS
Comprehensive Cancer Center, Ohio State University, USA
10:15 - 10:45
Coffee Break
10:45 - 12:15
Oral Abstracts Session 2
Oral Abstracts Session 2 image
Jacques Galipeau, MD (Chair)
University of Wisconsin - Madison, USA
10:45 - 12:15
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy
Valkal Bhatt, PharmD, BCOP, BCPS (Chair)
Memorial Sloan Kettering Cancer Center, USA
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy image
Christina Bachmeier, PharmD, BCOP
Moffitt Cancer Center, USA
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy image
Rebecca Gonzalez, PharmD, BCOP
Moffitt Cancer Center, USA